ETF Holdings Breakdown of ZYME

Stock NameZymeworks Inc. Common Stock
TickerZYME(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINCA98985W1023

News associated with ZYME

Barclays PLC Purchases 66,506 Shares of Zymeworks Inc. (NYSE:ZYME)
Barclays PLC raised its position in Zymeworks Inc. (NYSE:ZYME – Free Report) by 43.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 220,890 shares of the company’s stock after purchasing an additional 66,506 shares during the quarter. Barclays PLC’s holdings in Zymeworks […] - 2025-04-29 08:22:53
Legal & General Group Plc Acquires 2,590 Shares of Zymeworks Inc. (NYSE:ZYME)
Legal & General Group Plc increased its holdings in Zymeworks Inc. (NYSE:ZYME – Free Report) by 5.8% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 47,082 shares of the company’s stock after buying an additional 2,590 shares during the quarter. Legal & General Group Plc’s holdings […] - 2025-04-29 07:50:50
Russell Investments Group Ltd. Cuts Stake in Zymeworks Inc. (NYSE:ZYME)
Russell Investments Group Ltd. reduced its holdings in shares of Zymeworks Inc. (NYSE:ZYME – Free Report) by 9.7% during the fourth quarter, Holdings Channel reports. The fund owned 44,945 shares of the company’s stock after selling 4,826 shares during the period. Russell Investments Group Ltd.’s holdings in Zymeworks were worth $658,000 at the end of […] - 2025-04-23 08:20:54
Geode Capital Management LLC Reduces Stock Position in Zymeworks Inc. (NYSE:ZYME)
Geode Capital Management LLC trimmed its holdings in shares of Zymeworks Inc. (NYSE:ZYME – Free Report) by 3.4% in the fourth quarter, Holdings Channel reports. The institutional investor owned 689,884 shares of the company’s stock after selling 24,031 shares during the period. Geode Capital Management LLC’s holdings in Zymeworks were worth $10,100,000 as of its […] - 2025-04-23 07:27:03
Renaissance Technologies LLC Increases Stock Holdings in Zymeworks Inc. (NYSE:ZYME)
Renaissance Technologies LLC increased its holdings in shares of Zymeworks Inc. (NYSE:ZYME – Free Report) by 54.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 285,700 shares of the company’s stock after buying an additional 101,100 shares during the quarter. Renaissance Technologies […] - 2025-04-22 08:04:52
XTX Topco Ltd Invests $493,000 in Zymeworks Inc. (NYSE:ZYME)
XTX Topco Ltd acquired a new position in shares of Zymeworks Inc. (NYSE:ZYME – Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 33,702 shares of the company’s stock, valued at approximately $493,000. Other hedge funds have also made changes to their positions in the […] - 2025-04-21 08:44:47
Federated Hermes Inc. Has $2.66 Million Holdings in Zymeworks Inc. (NYSE:ZYME)
Federated Hermes Inc. grew its holdings in Zymeworks Inc. (NYSE:ZYME – Free Report) by 1.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 181,626 shares of the company’s stock after buying an additional 3,367 shares during the period. Federated […] - 2025-04-14 08:15:00
Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Purchases 196,438 Shares
Zymeworks Inc. (NYSE:ZYME – Get Free Report) Director Ecor1 Capital, Llc purchased 196,438 shares of the firm’s stock in a transaction that occurred on Friday, April 4th. The stock was acquired at an average price of $11.17 per share, with a total value of $2,194,212.46. Following the completion of the purchase, the director now owns […] - 2025-04-09 08:05:20
Zymeworks Inc. (NYSE:ZYME) Given Average Rating of “Moderate Buy” by Brokerages
Shares of Zymeworks Inc. (NYSE:ZYME – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on […] - 2025-04-07 06:06:59
Schroder Investment Management Group Acquires New Shares in Zymeworks Inc. (NYSE:ZYME)
Schroder Investment Management Group bought a new position in Zymeworks Inc. (NYSE:ZYME – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 337,161 shares of the company’s stock, valued at approximately $4,892,000. A number of other hedge funds have also added to […] - 2025-04-06 08:29:07
Zymeworks (NYSE:ZYME) Coverage Initiated by Analysts at Lifesci Capital
Lifesci Capital initiated coverage on shares of Zymeworks (NYSE:ZYME – Free Report) in a research note published on Tuesday,Benzinga reports. The brokerage issued an outperform rating and a $30.00 target price on the stock. A number of other research analysts have also recently commented on ZYME. JPMorgan Chase & Co. upgraded Zymeworks from a “neutral” […] - 2025-03-12 07:08:49
HC Wainwright Issues Positive Forecast for Zymeworks (NYSE:ZYME) Stock Price
Zymeworks (NYSE:ZYME – Free Report) had its target price raised by HC Wainwright from $12.00 to $13.00 in a research note issued to investors on Monday,Benzinga reports. HC Wainwright currently has a neutral rating on the stock. ZYME has been the topic of several other research reports. Wells Fargo & Company raised their price target […] - 2025-03-11 06:02:50
Citigroup Forecasts Strong Price Appreciation for Zymeworks (NYSE:ZYME) Stock
Zymeworks (NYSE:ZYME – Free Report) had its target price raised by Citigroup from $18.00 to $19.00 in a report released on Friday morning,Benzinga reports. Citigroup currently has a buy rating on the stock. A number of other research firms have also weighed in on ZYME. Wells Fargo & Company raised their target price on Zymeworks […] - 2025-03-10 06:44:48
New York State Common Retirement Fund Purchases 4,000 Shares of Zymeworks Inc. (NYSE:ZYME)
New York State Common Retirement Fund lifted its position in Zymeworks Inc. (NYSE:ZYME – Free Report) by 42.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 13,371 shares of the company’s stock after buying an additional 4,000 shares during the period. […] - 2025-03-06 10:19:23
Zymeworks Inc. (NYSE:ZYME) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Zymeworks Inc. (NYSE:ZYME – Get Free Report) has been given a consensus rating of “Moderate Buy” by the seven research firms that are currently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation […] - 2025-02-21 07:10:59

ZYME institutional holdings

The following institutional investment holdings of ZYME have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 92,921USD 1,051,866
2025-05-08 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 80,526USD 911,554
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 32,694USD 370,096
2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 32,694USD 370,096 -0.2%
2025-05-08 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 1,877USD 21,248
Total =240,712 USD 2,724,860
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.